nodes	percent_of_prediction	percent_of_DWPC	metapath
Regorafenib—RET—Signaling events regulated by Ret tyrosine kinase—FRS2—nasal cavity cancer	0.0259	0.0259	CbGpPWpGaD
Regorafenib—NTRK1—Frs2-mediated activation—FRS2—nasal cavity cancer	0.0209	0.0209	CbGpPWpGaD
Regorafenib—MAPK11—CXCR3-mediated signaling events—CXCL11—nasal cavity cancer	0.0206	0.0206	CbGpPWpGaD
Regorafenib—NTRK1—Prolonged ERK activation events—FRS2—nasal cavity cancer	0.0197	0.0197	CbGpPWpGaD
Regorafenib—BRAF—Frs2-mediated activation—FRS2—nasal cavity cancer	0.0168	0.0168	CbGpPWpGaD
Regorafenib—TEK—SHP2 signaling—FRS2—nasal cavity cancer	0.0168	0.0168	CbGpPWpGaD
Regorafenib—BRAF—Prolonged ERK activation events—FRS2—nasal cavity cancer	0.0158	0.0158	CbGpPWpGaD
Regorafenib—RAF1—CXCR3-mediated signaling events—CXCL11—nasal cavity cancer	0.0141	0.0141	CbGpPWpGaD
Regorafenib—NTRK1—Signalling to ERKs—FRS2—nasal cavity cancer	0.0133	0.0133	CbGpPWpGaD
Regorafenib—RAF1—Frs2-mediated activation—FRS2—nasal cavity cancer	0.0117	0.0117	CbGpPWpGaD
Regorafenib—BRAF—Negative regulation of FGFR signaling—FRS2—nasal cavity cancer	0.0116	0.0116	CbGpPWpGaD
Regorafenib—RAF1—Prolonged ERK activation events—FRS2—nasal cavity cancer	0.011	0.011	CbGpPWpGaD
Regorafenib—MAPK11—Signalling to ERKs—FRS2—nasal cavity cancer	0.0108	0.0108	CbGpPWpGaD
Regorafenib—FGFR2—Negative regulation of FGFR signaling—FRS2—nasal cavity cancer	0.0107	0.0107	CbGpPWpGaD
Regorafenib—BRAF—Signalling to ERKs—FRS2—nasal cavity cancer	0.0107	0.0107	CbGpPWpGaD
Regorafenib—NTRK1—SHP2 signaling—FRS2—nasal cavity cancer	0.0107	0.0107	CbGpPWpGaD
Regorafenib—NTRK1—Neurotrophic factor-mediated Trk receptor signaling—FRS2—nasal cavity cancer	0.0102	0.0102	CbGpPWpGaD
Regorafenib—KDR—SHP2 signaling—FRS2—nasal cavity cancer	0.0101	0.0101	CbGpPWpGaD
Regorafenib—FGFR1—Negative regulation of FGFR signaling—FRS2—nasal cavity cancer	0.00999	0.00999	CbGpPWpGaD
Regorafenib—FGFR2—FRS2-mediated cascade—FRS2—nasal cavity cancer	0.00993	0.00993	CbGpPWpGaD
Regorafenib—PDGFRA—Allograft Rejection—CXCL11—nasal cavity cancer	0.00981	0.00981	CbGpPWpGaD
Regorafenib—FGFR2—Signaling by FGFR mutants—FRS2—nasal cavity cancer	0.00975	0.00975	CbGpPWpGaD
Regorafenib—MAPK11—Toll-like Receptor Signaling Pathway—CXCL11—nasal cavity cancer	0.00937	0.00937	CbGpPWpGaD
Regorafenib—FGFR1—FRS2-mediated cascade—FRS2—nasal cavity cancer	0.00926	0.00926	CbGpPWpGaD
Regorafenib—FGFR1—Signaling by FGFR mutants—FRS2—nasal cavity cancer	0.00909	0.00909	CbGpPWpGaD
Regorafenib—FGFR2—FGF signaling pathway—FRS2—nasal cavity cancer	0.00843	0.00843	CbGpPWpGaD
Regorafenib—FGFR1—FGF signaling pathway—FRS2—nasal cavity cancer	0.00786	0.00786	CbGpPWpGaD
Regorafenib—RAF1—Signalling to ERKs—FRS2—nasal cavity cancer	0.00741	0.00741	CbGpPWpGaD
Regorafenib—RAF1—FRS2-mediated cascade—FRS2—nasal cavity cancer	0.00741	0.00741	CbGpPWpGaD
Regorafenib—MAPK11—Regulation of toll-like receptor signaling pathway—CXCL11—nasal cavity cancer	0.00731	0.00731	CbGpPWpGaD
Regorafenib—FGFR2—PI3K Cascade—FRS2—nasal cavity cancer	0.00701	0.00701	CbGpPWpGaD
Regorafenib—NTRK1—PI3K/AKT activation—FRS2—nasal cavity cancer	0.00685	0.00685	CbGpPWpGaD
Regorafenib—PDGFRB—SHP2 signaling—FRS2—nasal cavity cancer	0.00667	0.00667	CbGpPWpGaD
Regorafenib—FGFR1—PI3K Cascade—FRS2—nasal cavity cancer	0.00653	0.00653	CbGpPWpGaD
Regorafenib—ABL1—Neurotrophic factor-mediated Trk receptor signaling—FRS2—nasal cavity cancer	0.00624	0.00624	CbGpPWpGaD
Regorafenib—RAF1—SHP2 signaling—FRS2—nasal cavity cancer	0.00594	0.00594	CbGpPWpGaD
Regorafenib—FGFR2—IRS-mediated signalling—FRS2—nasal cavity cancer	0.00586	0.00586	CbGpPWpGaD
Regorafenib—FGFR2—Constitutive PI3K/AKT Signaling in Cancer—FRS2—nasal cavity cancer	0.00581	0.00581	CbGpPWpGaD
Regorafenib—KIT—Constitutive PI3K/AKT Signaling in Cancer—FRS2—nasal cavity cancer	0.00571	0.00571	CbGpPWpGaD
Regorafenib—FGFR2—IRS-related events—FRS2—nasal cavity cancer	0.0057	0.0057	CbGpPWpGaD
Regorafenib—FGFR2—IRS-related events triggered by IGF1R—FRS2—nasal cavity cancer	0.00565	0.00565	CbGpPWpGaD
Regorafenib—FGFR2—IGF1R signaling cascade—FRS2—nasal cavity cancer	0.0055	0.0055	CbGpPWpGaD
Regorafenib—FGFR2—Insulin receptor signalling cascade—FRS2—nasal cavity cancer	0.0055	0.0055	CbGpPWpGaD
Regorafenib—FGFR1—IRS-mediated signalling—FRS2—nasal cavity cancer	0.00547	0.00547	CbGpPWpGaD
Regorafenib—FGFR1—Constitutive PI3K/AKT Signaling in Cancer—FRS2—nasal cavity cancer	0.00541	0.00541	CbGpPWpGaD
Regorafenib—PDGFRA—Constitutive PI3K/AKT Signaling in Cancer—FRS2—nasal cavity cancer	0.0054	0.0054	CbGpPWpGaD
Regorafenib—FGFR1—IRS-related events—FRS2—nasal cavity cancer	0.00532	0.00532	CbGpPWpGaD
Regorafenib—FGFR1—IRS-related events triggered by IGF1R—FRS2—nasal cavity cancer	0.00527	0.00527	CbGpPWpGaD
Regorafenib—FGFR2—PI-3K cascade—FRS2—nasal cavity cancer	0.00523	0.00523	CbGpPWpGaD
Regorafenib—NTRK1—BDNF signaling pathway—FRS2—nasal cavity cancer	0.00516	0.00516	CbGpPWpGaD
Regorafenib—KIT—PI-3K cascade—FRS2—nasal cavity cancer	0.00514	0.00514	CbGpPWpGaD
Regorafenib—FGFR1—Insulin receptor signalling cascade—FRS2—nasal cavity cancer	0.00513	0.00513	CbGpPWpGaD
Regorafenib—FGFR1—IGF1R signaling cascade—FRS2—nasal cavity cancer	0.00513	0.00513	CbGpPWpGaD
Regorafenib—FGFR2—PI3K/AKT activation—FRS2—nasal cavity cancer	0.00511	0.00511	CbGpPWpGaD
Regorafenib—FGFR2—GAB1 signalosome—FRS2—nasal cavity cancer	0.00507	0.00507	CbGpPWpGaD
Regorafenib—KIT—PI3K/AKT activation—FRS2—nasal cavity cancer	0.00502	0.00502	CbGpPWpGaD
Regorafenib—KIT—GAB1 signalosome—FRS2—nasal cavity cancer	0.00498	0.00498	CbGpPWpGaD
Regorafenib—FGFR2—Role of LAT2/NTAL/LAB on calcium mobilization—FRS2—nasal cavity cancer	0.00495	0.00495	CbGpPWpGaD
Regorafenib—FGFR1—PI-3K cascade—FRS2—nasal cavity cancer	0.00488	0.00488	CbGpPWpGaD
Regorafenib—PDGFRB—Constitutive PI3K/AKT Signaling in Cancer—FRS2—nasal cavity cancer	0.00487	0.00487	CbGpPWpGaD
Regorafenib—PDGFRA—PI-3K cascade—FRS2—nasal cavity cancer	0.00487	0.00487	CbGpPWpGaD
Regorafenib—KIT—Role of LAT2/NTAL/LAB on calcium mobilization—FRS2—nasal cavity cancer	0.00486	0.00486	CbGpPWpGaD
Regorafenib—FGFR1—PI3K/AKT activation—FRS2—nasal cavity cancer	0.00476	0.00476	CbGpPWpGaD
Regorafenib—PDGFRA—PI3K/AKT activation—FRS2—nasal cavity cancer	0.00475	0.00475	CbGpPWpGaD
Regorafenib—FGFR1—GAB1 signalosome—FRS2—nasal cavity cancer	0.00472	0.00472	CbGpPWpGaD
Regorafenib—PDGFRA—GAB1 signalosome—FRS2—nasal cavity cancer	0.00471	0.00471	CbGpPWpGaD
Regorafenib—FGFR1—Role of LAT2/NTAL/LAB on calcium mobilization—FRS2—nasal cavity cancer	0.00462	0.00462	CbGpPWpGaD
Regorafenib—PDGFRA—Role of LAT2/NTAL/LAB on calcium mobilization—FRS2—nasal cavity cancer	0.0046	0.0046	CbGpPWpGaD
Regorafenib—FGFR2—Signaling by Insulin receptor—FRS2—nasal cavity cancer	0.00457	0.00457	CbGpPWpGaD
Regorafenib—PDGFRB—PI-3K cascade—FRS2—nasal cavity cancer	0.00438	0.00438	CbGpPWpGaD
Regorafenib—RAF1—IRS-mediated signalling—FRS2—nasal cavity cancer	0.00438	0.00438	CbGpPWpGaD
Regorafenib—PDGFRB—PI3K/AKT activation—FRS2—nasal cavity cancer	0.00428	0.00428	CbGpPWpGaD
Regorafenib—FGFR1—Signaling by Insulin receptor—FRS2—nasal cavity cancer	0.00426	0.00426	CbGpPWpGaD
Regorafenib—RAF1—IRS-related events—FRS2—nasal cavity cancer	0.00426	0.00426	CbGpPWpGaD
Regorafenib—PDGFRB—GAB1 signalosome—FRS2—nasal cavity cancer	0.00424	0.00424	CbGpPWpGaD
Regorafenib—RAF1—IRS-related events triggered by IGF1R—FRS2—nasal cavity cancer	0.00422	0.00422	CbGpPWpGaD
Regorafenib—PDGFRB—Role of LAT2/NTAL/LAB on calcium mobilization—FRS2—nasal cavity cancer	0.00415	0.00415	CbGpPWpGaD
Regorafenib—RAF1—IGF1R signaling cascade—FRS2—nasal cavity cancer	0.00411	0.00411	CbGpPWpGaD
Regorafenib—RAF1—Insulin receptor signalling cascade—FRS2—nasal cavity cancer	0.00411	0.00411	CbGpPWpGaD
Regorafenib—FGFR2—Signaling by SCF-KIT—FRS2—nasal cavity cancer	0.00391	0.00391	CbGpPWpGaD
Regorafenib—NTRK1—NGF signalling via TRKA from the plasma membrane—FRS2—nasal cavity cancer	0.00387	0.00387	CbGpPWpGaD
Regorafenib—KIT—Signaling by SCF-KIT—FRS2—nasal cavity cancer	0.00384	0.00384	CbGpPWpGaD
Regorafenib—BRAF—Signaling by FGFR—FRS2—nasal cavity cancer	0.00378	0.00378	CbGpPWpGaD
Regorafenib—FGFR2—Downstream signaling of activated FGFR—FRS2—nasal cavity cancer	0.00374	0.00374	CbGpPWpGaD
Regorafenib—ABCB1—Allograft Rejection—CXCL11—nasal cavity cancer	0.00371	0.00371	CbGpPWpGaD
Regorafenib—FGFR2—Signaling by ERBB4—FRS2—nasal cavity cancer	0.00368	0.00368	CbGpPWpGaD
Regorafenib—KIT—Downstream signaling of activated FGFR—FRS2—nasal cavity cancer	0.00368	0.00368	CbGpPWpGaD
Regorafenib—FGFR1—Signaling by SCF-KIT—FRS2—nasal cavity cancer	0.00365	0.00365	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling by SCF-KIT—FRS2—nasal cavity cancer	0.00364	0.00364	CbGpPWpGaD
Regorafenib—KIT—Signaling by ERBB4—FRS2—nasal cavity cancer	0.00362	0.00362	CbGpPWpGaD
Regorafenib—BRAF—Signaling by FGFR in disease—FRS2—nasal cavity cancer	0.00352	0.00352	CbGpPWpGaD
Regorafenib—FGFR2—Downstream signal transduction—FRS2—nasal cavity cancer	0.00352	0.00352	CbGpPWpGaD
Regorafenib—FGFR2—Signaling by FGFR—FRS2—nasal cavity cancer	0.0035	0.0035	CbGpPWpGaD
Regorafenib—FGFR1—Downstream signaling of activated FGFR—FRS2—nasal cavity cancer	0.00349	0.00349	CbGpPWpGaD
Regorafenib—FGFR2—Signaling by ERBB2—FRS2—nasal cavity cancer	0.00348	0.00348	CbGpPWpGaD
Regorafenib—PDGFRA—Downstream signaling of activated FGFR—FRS2—nasal cavity cancer	0.00348	0.00348	CbGpPWpGaD
Regorafenib—FGFR2—DAP12 signaling—FRS2—nasal cavity cancer	0.00347	0.00347	CbGpPWpGaD
Regorafenib—KIT—Downstream signal transduction—FRS2—nasal cavity cancer	0.00345	0.00345	CbGpPWpGaD
Regorafenib—KIT—Signaling by FGFR—FRS2—nasal cavity cancer	0.00344	0.00344	CbGpPWpGaD
Regorafenib—FGFR1—Signaling by ERBB4—FRS2—nasal cavity cancer	0.00343	0.00343	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling by ERBB4—FRS2—nasal cavity cancer	0.00342	0.00342	CbGpPWpGaD
Regorafenib—KIT—Signaling by ERBB2—FRS2—nasal cavity cancer	0.00342	0.00342	CbGpPWpGaD
Regorafenib—FGFR2—Downstream signaling events of B Cell Receptor (BCR)—FRS2—nasal cavity cancer	0.00342	0.00342	CbGpPWpGaD
Regorafenib—RAF1—Signaling by Insulin receptor—FRS2—nasal cavity cancer	0.00341	0.00341	CbGpPWpGaD
Regorafenib—KIT—DAP12 signaling—FRS2—nasal cavity cancer	0.0034	0.0034	CbGpPWpGaD
Regorafenib—KIT—Downstream signaling events of B Cell Receptor (BCR)—FRS2—nasal cavity cancer	0.00336	0.00336	CbGpPWpGaD
Regorafenib—FGFR1—Downstream signal transduction—FRS2—nasal cavity cancer	0.00328	0.00328	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling by SCF-KIT—FRS2—nasal cavity cancer	0.00328	0.00328	CbGpPWpGaD
Regorafenib—PDGFRA—Downstream signal transduction—FRS2—nasal cavity cancer	0.00327	0.00327	CbGpPWpGaD
Regorafenib—FGFR1—Signaling by FGFR—FRS2—nasal cavity cancer	0.00326	0.00326	CbGpPWpGaD
Regorafenib—FGFR2—Signaling by FGFR in disease—FRS2—nasal cavity cancer	0.00326	0.00326	CbGpPWpGaD
Regorafenib—FGFR2—DAP12 interactions—FRS2—nasal cavity cancer	0.00326	0.00326	CbGpPWpGaD
Regorafenib—FGFR2—Fc epsilon receptor (FCERI) signaling—FRS2—nasal cavity cancer	0.00326	0.00326	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling by FGFR—FRS2—nasal cavity cancer	0.00325	0.00325	CbGpPWpGaD
Regorafenib—FGFR1—Signaling by ERBB2—FRS2—nasal cavity cancer	0.00325	0.00325	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling by ERBB2—FRS2—nasal cavity cancer	0.00324	0.00324	CbGpPWpGaD
Regorafenib—FGFR2—Signaling by EGFR—FRS2—nasal cavity cancer	0.00323	0.00323	CbGpPWpGaD
Regorafenib—FGFR1—DAP12 signaling—FRS2—nasal cavity cancer	0.00323	0.00323	CbGpPWpGaD
Regorafenib—PDGFRA—DAP12 signaling—FRS2—nasal cavity cancer	0.00322	0.00322	CbGpPWpGaD
Regorafenib—FGFR2—Signaling by EGFR in Cancer—FRS2—nasal cavity cancer	0.0032	0.0032	CbGpPWpGaD
Regorafenib—KIT—Signaling by FGFR in disease—FRS2—nasal cavity cancer	0.0032	0.0032	CbGpPWpGaD
Regorafenib—KIT—DAP12 interactions—FRS2—nasal cavity cancer	0.0032	0.0032	CbGpPWpGaD
Regorafenib—KIT—Fc epsilon receptor (FCERI) signaling—FRS2—nasal cavity cancer	0.0032	0.0032	CbGpPWpGaD
Regorafenib—FGFR2—Signaling by PDGF—FRS2—nasal cavity cancer	0.00319	0.00319	CbGpPWpGaD
Regorafenib—FGFR1—Downstream signaling events of B Cell Receptor (BCR)—FRS2—nasal cavity cancer	0.00318	0.00318	CbGpPWpGaD
Regorafenib—PDGFRA—Downstream signaling events of B Cell Receptor (BCR)—FRS2—nasal cavity cancer	0.00318	0.00318	CbGpPWpGaD
Regorafenib—KIT—Signaling by EGFR—FRS2—nasal cavity cancer	0.00317	0.00317	CbGpPWpGaD
Regorafenib—KIT—Signaling by EGFR in Cancer—FRS2—nasal cavity cancer	0.00315	0.00315	CbGpPWpGaD
Regorafenib—MAPK11—NGF signalling via TRKA from the plasma membrane—FRS2—nasal cavity cancer	0.00315	0.00315	CbGpPWpGaD
Regorafenib—PDGFRB—Downstream signaling of activated FGFR—FRS2—nasal cavity cancer	0.00313	0.00313	CbGpPWpGaD
Regorafenib—KIT—Signaling by PDGF—FRS2—nasal cavity cancer	0.00313	0.00313	CbGpPWpGaD
Regorafenib—BRAF—NGF signalling via TRKA from the plasma membrane—FRS2—nasal cavity cancer	0.00312	0.00312	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling by ERBB4—FRS2—nasal cavity cancer	0.00309	0.00309	CbGpPWpGaD
Regorafenib—FGFR1—Fc epsilon receptor (FCERI) signaling—FRS2—nasal cavity cancer	0.00304	0.00304	CbGpPWpGaD
Regorafenib—FGFR1—DAP12 interactions—FRS2—nasal cavity cancer	0.00304	0.00304	CbGpPWpGaD
Regorafenib—FGFR1—Signaling by FGFR in disease—FRS2—nasal cavity cancer	0.00304	0.00304	CbGpPWpGaD
Regorafenib—PDGFRA—Fc epsilon receptor (FCERI) signaling—FRS2—nasal cavity cancer	0.00303	0.00303	CbGpPWpGaD
Regorafenib—PDGFRA—DAP12 interactions—FRS2—nasal cavity cancer	0.00303	0.00303	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling by FGFR in disease—FRS2—nasal cavity cancer	0.00303	0.00303	CbGpPWpGaD
Regorafenib—FGFR2—B Cell Activation—FRS2—nasal cavity cancer	0.00302	0.00302	CbGpPWpGaD
Regorafenib—FGFR1—Signaling by EGFR—FRS2—nasal cavity cancer	0.00301	0.00301	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling by EGFR—FRS2—nasal cavity cancer	0.003	0.003	CbGpPWpGaD
Regorafenib—FGFR1—Signaling by EGFR in Cancer—FRS2—nasal cavity cancer	0.00299	0.00299	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling by EGFR in Cancer—FRS2—nasal cavity cancer	0.00298	0.00298	CbGpPWpGaD
Regorafenib—NTRK1—Signaling by NGF—FRS2—nasal cavity cancer	0.00298	0.00298	CbGpPWpGaD
Regorafenib—FGFR1—Signaling by PDGF—FRS2—nasal cavity cancer	0.00297	0.00297	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling by PDGF—FRS2—nasal cavity cancer	0.00296	0.00296	CbGpPWpGaD
Regorafenib—KIT—B Cell Activation—FRS2—nasal cavity cancer	0.00296	0.00296	CbGpPWpGaD
Regorafenib—PDGFRB—Downstream signal transduction—FRS2—nasal cavity cancer	0.00295	0.00295	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling by FGFR—FRS2—nasal cavity cancer	0.00293	0.00293	CbGpPWpGaD
Regorafenib—RAF1—Signaling by SCF-KIT—FRS2—nasal cavity cancer	0.00292	0.00292	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling by ERBB2—FRS2—nasal cavity cancer	0.00292	0.00292	CbGpPWpGaD
Regorafenib—PDGFRB—DAP12 signaling—FRS2—nasal cavity cancer	0.0029	0.0029	CbGpPWpGaD
Regorafenib—FGFR2—NGF signalling via TRKA from the plasma membrane—FRS2—nasal cavity cancer	0.00289	0.00289	CbGpPWpGaD
Regorafenib—RAF1—BDNF signaling pathway—FRS2—nasal cavity cancer	0.00287	0.00287	CbGpPWpGaD
Regorafenib—PDGFRB—Downstream signaling events of B Cell Receptor (BCR)—FRS2—nasal cavity cancer	0.00286	0.00286	CbGpPWpGaD
Regorafenib—KIT—NGF signalling via TRKA from the plasma membrane—FRS2—nasal cavity cancer	0.00284	0.00284	CbGpPWpGaD
Regorafenib—FGFR1—B Cell Activation—FRS2—nasal cavity cancer	0.00281	0.00281	CbGpPWpGaD
Regorafenib—PDGFRA—B Cell Activation—FRS2—nasal cavity cancer	0.00281	0.00281	CbGpPWpGaD
Regorafenib—RAF1—Downstream signaling of activated FGFR—FRS2—nasal cavity cancer	0.00279	0.00279	CbGpPWpGaD
Regorafenib—RAF1—Signaling by ERBB4—FRS2—nasal cavity cancer	0.00275	0.00275	CbGpPWpGaD
Regorafenib—PDGFRB—DAP12 interactions—FRS2—nasal cavity cancer	0.00273	0.00273	CbGpPWpGaD
Regorafenib—PDGFRB—Fc epsilon receptor (FCERI) signaling—FRS2—nasal cavity cancer	0.00273	0.00273	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling by FGFR in disease—FRS2—nasal cavity cancer	0.00273	0.00273	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling by EGFR—FRS2—nasal cavity cancer	0.00271	0.00271	CbGpPWpGaD
Regorafenib—FGFR1—NGF signalling via TRKA from the plasma membrane—FRS2—nasal cavity cancer	0.00269	0.00269	CbGpPWpGaD
Regorafenib—PDGFRA—NGF signalling via TRKA from the plasma membrane—FRS2—nasal cavity cancer	0.00269	0.00269	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling by EGFR in Cancer—FRS2—nasal cavity cancer	0.00268	0.00268	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling by PDGF—FRS2—nasal cavity cancer	0.00267	0.00267	CbGpPWpGaD
Regorafenib—RAF1—Downstream signal transduction—FRS2—nasal cavity cancer	0.00263	0.00263	CbGpPWpGaD
Regorafenib—RAF1—Signaling by FGFR—FRS2—nasal cavity cancer	0.00261	0.00261	CbGpPWpGaD
Regorafenib—RAF1—Signaling by ERBB2—FRS2—nasal cavity cancer	0.0026	0.0026	CbGpPWpGaD
Regorafenib—RAF1—DAP12 signaling—FRS2—nasal cavity cancer	0.00259	0.00259	CbGpPWpGaD
Regorafenib—PDGFRB—B Cell Activation—FRS2—nasal cavity cancer	0.00253	0.00253	CbGpPWpGaD
Regorafenib—RAF1—DAP12 interactions—FRS2—nasal cavity cancer	0.00243	0.00243	CbGpPWpGaD
Regorafenib—RAF1—Fc epsilon receptor (FCERI) signaling—FRS2—nasal cavity cancer	0.00243	0.00243	CbGpPWpGaD
Regorafenib—RAF1—Signaling by FGFR in disease—FRS2—nasal cavity cancer	0.00243	0.00243	CbGpPWpGaD
Regorafenib—MAPK11—Signaling by NGF—FRS2—nasal cavity cancer	0.00242	0.00242	CbGpPWpGaD
Regorafenib—PDGFRB—NGF signalling via TRKA from the plasma membrane—FRS2—nasal cavity cancer	0.00242	0.00242	CbGpPWpGaD
Regorafenib—RAF1—Signaling by EGFR—FRS2—nasal cavity cancer	0.00241	0.00241	CbGpPWpGaD
Regorafenib—BRAF—Signaling by NGF—FRS2—nasal cavity cancer	0.0024	0.0024	CbGpPWpGaD
Regorafenib—RAF1—Signaling by EGFR in Cancer—FRS2—nasal cavity cancer	0.00239	0.00239	CbGpPWpGaD
Regorafenib—RAF1—Signaling by PDGF—FRS2—nasal cavity cancer	0.00238	0.00238	CbGpPWpGaD
Regorafenib—FGFR2—Signaling by NGF—FRS2—nasal cavity cancer	0.00222	0.00222	CbGpPWpGaD
Regorafenib—KIT—Signaling by NGF—FRS2—nasal cavity cancer	0.00218	0.00218	CbGpPWpGaD
Regorafenib—RAF1—NGF signalling via TRKA from the plasma membrane—FRS2—nasal cavity cancer	0.00216	0.00216	CbGpPWpGaD
Regorafenib—FGFR1—Signaling by NGF—FRS2—nasal cavity cancer	0.00207	0.00207	CbGpPWpGaD
Regorafenib—FLT4—Signaling Pathways—CXCL11—nasal cavity cancer	0.00207	0.00207	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling by NGF—FRS2—nasal cavity cancer	0.00207	0.00207	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling by NGF—FRS2—nasal cavity cancer	0.00186	0.00186	CbGpPWpGaD
Regorafenib—RAF1—Signaling by NGF—FRS2—nasal cavity cancer	0.00166	0.00166	CbGpPWpGaD
Regorafenib—FLT1—Signaling Pathways—CXCL11—nasal cavity cancer	0.00154	0.00154	CbGpPWpGaD
Regorafenib—MAPK11—Innate Immune System—FRS2—nasal cavity cancer	0.00138	0.00138	CbGpPWpGaD
Regorafenib—FGFR2—Innate Immune System—FRS2—nasal cavity cancer	0.00127	0.00127	CbGpPWpGaD
Regorafenib—KIT—Innate Immune System—FRS2—nasal cavity cancer	0.00124	0.00124	CbGpPWpGaD
Regorafenib—FLT4—Signaling Pathways—FRS2—nasal cavity cancer	0.00122	0.00122	CbGpPWpGaD
Regorafenib—FGFR2—Adaptive Immune System—FRS2—nasal cavity cancer	0.00122	0.00122	CbGpPWpGaD
Regorafenib—KIT—Adaptive Immune System—FRS2—nasal cavity cancer	0.00119	0.00119	CbGpPWpGaD
Regorafenib—FGFR1—Innate Immune System—FRS2—nasal cavity cancer	0.00118	0.00118	CbGpPWpGaD
Regorafenib—PDGFRA—Innate Immune System—FRS2—nasal cavity cancer	0.00118	0.00118	CbGpPWpGaD
Regorafenib—FGFR1—Adaptive Immune System—FRS2—nasal cavity cancer	0.00113	0.00113	CbGpPWpGaD
Regorafenib—PDGFRA—Adaptive Immune System—FRS2—nasal cavity cancer	0.00113	0.00113	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—CXCL11—nasal cavity cancer	0.00109	0.00109	CbGpPWpGaD
Regorafenib—PDGFRB—Innate Immune System—FRS2—nasal cavity cancer	0.00106	0.00106	CbGpPWpGaD
Regorafenib—ABL1—Innate Immune System—FRS2—nasal cavity cancer	0.00103	0.00103	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—CXCL11—nasal cavity cancer	0.00103	0.00103	CbGpPWpGaD
Regorafenib—RAF1—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00102	0.00102	CbGpPWpGaD
Regorafenib—PDGFRB—Adaptive Immune System—FRS2—nasal cavity cancer	0.00102	0.00102	CbGpPWpGaD
Regorafenib—RAF1—Innate Immune System—FRS2—nasal cavity cancer	0.000946	0.000946	CbGpPWpGaD
Regorafenib—FLT1—Signaling Pathways—FRS2—nasal cavity cancer	0.000908	0.000908	CbGpPWpGaD
Regorafenib—RAF1—Adaptive Immune System—FRS2—nasal cavity cancer	0.000908	0.000908	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—CXCL11—nasal cavity cancer	0.000882	0.000882	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—CXCL11—nasal cavity cancer	0.000874	0.000874	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—CXCL11—nasal cavity cancer	0.00081	0.00081	CbGpPWpGaD
Regorafenib—MAPK11—Immune System—FRS2—nasal cavity cancer	0.000804	0.000804	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—CXCL11—nasal cavity cancer	0.000795	0.000795	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—CXCL11—nasal cavity cancer	0.000755	0.000755	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—CXCL11—nasal cavity cancer	0.000753	0.000753	CbGpPWpGaD
Regorafenib—FGFR2—Immune System—FRS2—nasal cavity cancer	0.000738	0.000738	CbGpPWpGaD
Regorafenib—BRAF—Disease—FRS2—nasal cavity cancer	0.000735	0.000735	CbGpPWpGaD
Regorafenib—KIT—Immune System—FRS2—nasal cavity cancer	0.000725	0.000725	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—FRS2—nasal cavity cancer	0.000688	0.000688	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—FRS2—nasal cavity cancer	0.000686	0.000686	CbGpPWpGaD
Regorafenib—FGFR2—Disease—FRS2—nasal cavity cancer	0.000681	0.000681	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—CXCL11—nasal cavity cancer	0.000678	0.000678	CbGpPWpGaD
Regorafenib—KIT—Disease—FRS2—nasal cavity cancer	0.000669	0.000669	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—FRS2—nasal cavity cancer	0.00064	0.00064	CbGpPWpGaD
Regorafenib—FGFR1—Disease—FRS2—nasal cavity cancer	0.000635	0.000635	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—FRS2—nasal cavity cancer	0.000633	0.000633	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—FRS2—nasal cavity cancer	0.000618	0.000618	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—FRS2—nasal cavity cancer	0.000604	0.000604	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—CXCL11—nasal cavity cancer	0.000604	0.000604	CbGpPWpGaD
Regorafenib—ABL1—Immune System—FRS2—nasal cavity cancer	0.000602	0.000602	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—FRS2—nasal cavity cancer	0.000571	0.000571	CbGpPWpGaD
Regorafenib—RAF1—Immune System—FRS2—nasal cavity cancer	0.000551	0.000551	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—FRS2—nasal cavity cancer	0.00052	0.00052	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—FRS2—nasal cavity cancer	0.000515	0.000515	CbGpPWpGaD
Regorafenib—RAF1—Disease—FRS2—nasal cavity cancer	0.000509	0.000509	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—FRS2—nasal cavity cancer	0.000477	0.000477	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—FRS2—nasal cavity cancer	0.000469	0.000469	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—FRS2—nasal cavity cancer	0.000445	0.000445	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—FRS2—nasal cavity cancer	0.000444	0.000444	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—FRS2—nasal cavity cancer	0.0004	0.0004	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—FRS2—nasal cavity cancer	0.000356	0.000356	CbGpPWpGaD
